Person · CIK 1759241

Atlas Venture Opportunity Fund I

Shareholder at Kymera Therapeutics and Disc Medicine; 10% owner at Generation Bio and Vigil Neuroscience

Earlier: Q32 Bio, Dyne Therapeutics, Xilio Therapeutics, Third Harmonic Bio, Day One Biopharmaceuticals, Ikena Oncology, Magenta Therapeutics, Akero Therapeutics, Replimune Group and AVROBIO

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$129.1M

Noticed on Form 144$61.9M

Bought on Form 4$51.4M

Companies14

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Vigil Neuroscience VIGL	Common Stock	By Atlas Venture Fund XII, L.P.	4,808,896	Jan 11, 2022 · Filing · EDGAR
Q32 Bio	Common Stock	Directly	864,261	Mar 25, 2024 · Filing · EDGAR
Q32 Bio	Common Stock	By Atlas Venture Opportunity Fund II, L.P.	724,549	Mar 25, 2024 · Filing · EDGAR
Q32 Bio	Common Stock	By Atlas Venture Opportunity Fund I, L.P.	503,296	Mar 25, 2024 · Filing · EDGAR
Kymera Therapeutics KYMR	Common Stock	Directly	4,676,075	Mar 13, 2024 · Filing · EDGAR
Kymera Therapeutics KYMR	Common Stock	See footnote	828,830	Mar 13, 2024 · Filing · EDGAR
Dyne Therapeutics	Common Stock	Directly	1,458,691	Mar 1, 2024 · Filing · EDGAR
Dyne Therapeutics	Common Stock	See footnote	847,388	Mar 1, 2024 · Filing · EDGAR
Xilio Therapeutics	Common Stock	Directly	2,019,563	Feb 8, 2024 · Filing · EDGAR
Xilio Therapeutics	Common Stock	See footnote	734,546	Feb 8, 2024 · Filing · EDGAR
Disc Medicine GMTX	Common Stock	Directly	1,402,186	Jan 23, 2024 · Filing · EDGAR
Disc Medicine GMTX	Common Stock	See footnote	198,326	Jan 23, 2024 · Filing · EDGAR
Third Harmonic Bio	Common Stock	Directly	594,096	Sep 19, 2022 · Filing · EDGAR
Day One Biopharmaceuticals	Common Stock	Directly	793,116	Jul 1, 2022 · Filing · EDGAR
Day One Biopharmaceuticals	Common Stock	See footnote	991,396	Jun 17, 2022 · Filing · EDGAR
Day One Biopharmaceuticals	Series B Preferred Stock into Common Stock	See Footnote	741,396	Feb 1, 2021 · Filing · EDGAR
Ikena Oncology	Common Stock	Directly	1,241,935	Dec 14, 2021 · Filing · EDGAR
Ikena Oncology	Common Stock	See footnote	874,634	Mar 30, 2021 · Filing · EDGAR
Magenta Therapeutics	Common Stock	Directly	1,250,000	Jun 29, 2020 · Filing · EDGAR
Akero Therapeutics	Common Stock	See footnote	404,079	Feb 7, 2020 · Filing · EDGAR
Replimune Group	Common Stock	See footnote	1,100,000	Nov 18, 2019 · Filing · EDGAR
AVROBIO	Common Stock	See Footnote	810,811	Jul 19, 2019 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q1 2026	—	$2.3M	—
Q4 2025	—	$23M	—
Q3 2025	—	$5.2M	—
Q3 2024	—	$2.5M	—
Q2 2024	—	$162K	—
Q1 2024	$60.6M	$18.8M	—
Q4 2023	$11.7M	$6.1M	—
Q3 2023	$18.8M	$3.8M	—
Q1 2023	$3.8M	Not machine-readable	—
Q4 2022	$27.3M	Not machine-readable	$10M
Q3 2022	—	—	$5.1M
Q2 2022	—	—	$11.5M
Q1 2022	—	—	$7.5M
Q4 2021	$386K	Not machine-readable	$3M
Q3 2021	$5.6M	Not machine-readable	—
Q2 2021	$802K	Not machine-readable	$8M
Q1 2021	—	—	$2M
Q2 2019	—	—	$4.3M

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Kymera Therapeutics KYMR · Merrill Lynch · 10b5-1 plan adopted Dec 11, 2025 · 1 notice
Mar 2, 2026	25,000 · ~$2.3M	Mar 2, 2026	Not sold within 90 days	Filing · EDGAR
Disc Medicine GMTX · Merrill Lynch · No 10b5-1 plan stated · 8 notices
Dec 17, 2025	393 · ~$36K	Dec 17, 2025	Not sold within 90 days	Filing · EDGAR
Dec 16, 2025	10,898 · ~$1M	Dec 16, 2025	Not sold within 90 days	Filing · EDGAR
Dec 15, 2025	15,401 · ~$1.4M	Dec 15, 2025	Not sold within 90 days	Filing · EDGAR
Dec 12, 2025	23,701 · ~$2.2M	Dec 12, 2025	Not sold within 90 days	Filing · EDGAR
Oct 16, 2025	1,425 · ~$110K	Oct 16, 2025	Not sold within 90 days	Filing · EDGAR
Oct 15, 2025	22,160 · ~$1.6M	Oct 15, 2025	Not sold within 90 days	Filing · EDGAR
Oct 8, 2025	71,961 · ~$4.9M	Oct 8, 2025	Not sold within 90 days	Filing · EDGAR
Oct 7, 2025	18,039 · ~$1.2M	Oct 7, 2025	Not sold within 90 days	Filing · EDGAR
Disc Medicine GMTX · Btig · No 10b5-1 plan stated · 7 notices
Dec 16, 2025	25,000 · ~$2.3M	Dec 16, 2025	Not sold within 90 days	Filing · EDGAR
Dec 15, 2025	17,433 · ~$1.6M	Dec 15, 2025	Not sold within 90 days	Filing · EDGAR
Oct 17, 2025	35,000 · ~$3.1M	Oct 17, 2025	Not sold within 90 days	Filing · EDGAR
Mar 5, 2024	26,157 · ~$1.9M	Mar 5, 2024	Not sold within 90 days	Filing · EDGAR
Jan 23, 2024	82,500 · ~$5.6M	Jan 23, 2024	Partly sold Sold 67,500 in 2 sales, Jan 23 to Jan 23 · $4.6M likely match Form 4	Filing · EDGAR
Jan 10, 2024	20,000 · ~$1.3M	Jan 10, 2024	Sold as noticed Sold 20,000 at $64.00 on Jan 10 · $1.3M Form 4	Filing · EDGAR
Aug 15, 2023	72,931 · ~$3.8M	Aug 15, 2023	Partly sold Sold 2,000 at $54.80 on Aug 14 · $110K likely match Form 4	Filing · EDGAR
Kymera Therapeutics KYMR · Btig · No 10b5-1 plan stated · 3 notices
Dec 12, 2025	108 · ~$10K	Dec 12, 2025	Not sold within 90 days	Filing · EDGAR
Dec 11, 2025	976 · ~$86K	Dec 11, 2025	Not sold within 90 days	Filing · EDGAR
Dec 10, 2025	36,769 · ~$3.3M	Dec 10, 2025	Not sold within 90 days	Filing · EDGAR
Disc Medicine GMTX · Merrill Lynch · 10b5-1 plan adopted Jan 31, 2025 · 8 notices
Aug 22, 2025	2,287 · ~$137K	Aug 22, 2025	Not sold within 90 days	Filing · EDGAR
Aug 14, 2025	7,212 · ~$441K	Aug 14, 2025	Not sold within 90 days	Filing · EDGAR
Aug 13, 2025	24,962 · ~$1.5M	Aug 13, 2025	Not sold within 90 days	Filing · EDGAR
Aug 5, 2025	395 · ~$24K	Aug 5, 2025	Not sold within 90 days	Filing · EDGAR
Jul 30, 2025	8,492 · ~$508K	Jul 30, 2025	Not sold within 90 days	Filing · EDGAR
Jul 24, 2025	13,033 · ~$794K	Jul 24, 2025	Not sold within 90 days	Filing · EDGAR
Jul 23, 2025	29,837 · ~$1.8M	Jul 23, 2025	Not sold within 90 days	Filing · EDGAR
Jul 18, 2025	664 · ~$38K	Jul 18, 2025	Not sold within 90 days	Filing · EDGAR
Kymera Therapeutics KYMR · Merrill · 10b5-1 plan adopted Jan 22, 2024 · 8 notices
Jul 9, 2024	78,776 · ~$2.5M	Jul 9, 2024	Not sold within 90 days	Filing · EDGAR
Jun 13, 2024	1,770 · ~$61K	Jun 13, 2024	Not sold within 90 days	Filing · EDGAR
Jun 12, 2024	2,905 · ~$100K	Jun 12, 2024	Not sold within 90 days	Filing · EDGAR
Mar 15, 2024	12,454 · ~$492K	Mar 15, 2024	Not sold within 90 days	Filing · EDGAR
Mar 14, 2024	9,679 · ~$409K	Mar 14, 2024	Not sold within 90 days	Filing · EDGAR
Mar 13, 2024	24,165 · ~$1M	Mar 13, 2024	Partly sold Sold 22,779 at $42.19 on Mar 13 · $961K likely match Form 4	Filing · EDGAR
Mar 12, 2024	28,271 · ~$1.2M	Mar 12, 2024	Partly sold Sold 24,490 in 4 sales, Mar 11 to Mar 13 · $1M likely match Form 4	Filing · EDGAR
Mar 11, 2024	8,882 · ~$386K	Mar 11, 2024	Partly sold Sold 7,986 in 3 sales, Mar 11 to Mar 12 · $345K likely match Form 4	Filing · EDGAR
Dyne Therapeutics · Merrill · 10b5-1 plan adopted Jan 10, 2024 · 4 notices
Mar 1, 2024	50,000 · ~$1.3M	Feb 28, 2024	Partly sold Sold 48,346 in 2 sales, Feb 27 to Feb 28 · $1.2M likely match Form 4	Filing · EDGAR
Feb 28, 2024	25,000 · ~$615K	Feb 28, 2024	Partly sold Sold 23,505 at $24.38 on Feb 27 · $573K likely match Form 4	Filing · EDGAR
Feb 23, 2024	100,000 · ~$2.2M	Feb 23, 2024	Partly sold Sold 92,583 in 6 sales, Feb 26 to Feb 28 · $2.2M likely match Form 4	Filing · EDGAR
Feb 23, 2024	100,000 · ~$2.2M	Feb 23, 2024	Sold as noticed Sold 100,911 in 7 sales, Feb 21 to Feb 28 · $2.3M Form 4 (1) · Form 4 (2)	Filing · EDGAR
Disc Medicine GMTX · Merrill Lynch, Pierce, Fenner & Smith · No 10b5-1 plan stated · 1 notice
Dec 12, 2023	100,000 · ~$6.1M	Dec 12, 2023	Sold as noticed Sold 100,466 in 16 sales, Dec 12 to Dec 14 · $6.2M Form 4	Filing · EDGAR
Sales without a matching Form 144 · 80 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice Kymera Therapeutics (KYMR): Sold 108,404 at $42.19 on Mar 13, 2024 · $4.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Kymera Therapeutics (KYMR): Sold 26,452 at $41.94 on Mar 12, 2024 · $1.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Kymera Therapeutics (KYMR): Sold 126,066 at $41.94 on Mar 12, 2024 · $5.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Kymera Therapeutics (KYMR): Sold 37,180 at $42.77 on Mar 11, 2024 · $1.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics: Sold 17,099 at $30.05 on Mar 1, 2024 · $514K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics: Sold 29,435 at $30.05 on Mar 1, 2024 · $885K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics: Sold 13,109 at $24.83 on Feb 28, 2024 · $325K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics: Sold 152,244 at $24.83 on Feb 28, 2024 · $3.8M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics: Sold 40,455 at $24.38 on Feb 27, 2024 · $986K (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics: Sold 272,923 at $24.38 on Feb 27, 2024 · $6.7M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics: Sold 136,312 at $23.59 on Feb 26, 2024 · $3.2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics: Sold 159,542 at $22.70 on Feb 23, 2024 · $3.6M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics: Sold 119,360 at $22.66 on Feb 22, 2024 · $2.7M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Dyne Therapeutics: Sold 149,337 at $22.44 on Feb 21, 2024 · $3.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Sold without notice Xilio Therapeutics: Sold 267 at $0.64 on Feb 8, 2024 · $171	Filing · EDGAR
—	—	—	Sold without notice Xilio Therapeutics: Sold 733 at $0.64 on Feb 8, 2024 · $469	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 82,500 at $67.65 on Jan 23, 2024 · $5.6M	Filing · EDGAR
—	—	—	Sold without notice Xilio Therapeutics: Sold 560 at $0.83 on Jan 12, 2024 · $465	Filing · EDGAR
—	—	—	Sold without notice Xilio Therapeutics: Sold 1,540 at $0.83 on Jan 12, 2024 · $1K	Filing · EDGAR
—	—	—	Sold without notice Xilio Therapeutics: Sold 569 at $0.87 on Jan 11, 2024 · $495	Filing · EDGAR
—	—	—	Sold without notice Xilio Therapeutics: Sold 1,566 at $0.87 on Jan 11, 2024 · $1K	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 30,000 at $64.00 on Jan 10, 2024 · $1.9M	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 20,429 at $58.27 on Dec 14, 2023 · $1.2M	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 30,645 at $58.27 on Dec 14, 2023 · $1.8M	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 3,508 at $59.99 on Dec 13, 2023 · $210K	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 6,599 at $65.77 on Dec 12, 2023 · $434K	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 9,901 at $65.77 on Dec 12, 2023 · $651K	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 18,615 at $65.10 on Dec 12, 2023 · $1.2M	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 72,931 at $52.40 on Aug 15, 2023 · $3.8M	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 111,069 at $52.40 on Aug 15, 2023 · $5.8M	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 98,000 at $53.00 on Aug 14, 2023 · $5.2M	Filing · EDGAR
—	—	—	Sold without notice Disc Medicine (GMTX): Sold 75,000 at $52.00 on Aug 14, 2023 · $3.9M	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 21,592 at $30.29 on Jan 12, 2023 · $654K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 77,128 at $30.29 on Jan 12, 2023 · $2.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 6,071 at $29.96 on Jan 11, 2023 · $182K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 21,683 at $29.96 on Jan 11, 2023 · $650K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 717 at $30.00 on Dec 15, 2022 · $22K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 2,561 at $30.00 on Dec 15, 2022 · $77K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 3,733 at $34.02 on Dec 14, 2022 · $127K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 3,919 at $33.34 on Dec 14, 2022 · $131K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 15,324 at $32.33 on Dec 14, 2022 · $495K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 28,329 at $31.44 on Dec 14, 2022 · $891K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 31,584 at $30.28 on Dec 14, 2022 · $956K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 13,335 at $34.02 on Dec 14, 2022 · $454K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 13,997 at $33.34 on Dec 14, 2022 · $467K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 54,737 at $32.33 on Dec 14, 2022 · $1.8M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 101,189 at $31.44 on Dec 14, 2022 · $3.2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 112,819 at $30.28 on Dec 14, 2022 · $3.4M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 21,085 at $30.00 on Nov 3, 2022 · $633K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 75,312 at $30.00 on Nov 3, 2022 · $2.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 27,038 at $30.02 on Nov 2, 2022 · $812K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 96,581 at $30.02 on Nov 2, 2022 · $2.9M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 1,044 at $31.08 on Nov 1, 2022 · $32K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 3,727 at $31.08 on Nov 1, 2022 · $116K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 15,804 at $30.57 on Nov 1, 2022 · $483K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 56,455 at $30.57 on Nov 1, 2022 · $1.7M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 26,383 at $30.23 on Oct 31, 2022 · $798K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 94,239 at $30.23 on Oct 31, 2022 · $2.8M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 19,915 at $30.00 on Oct 28, 2022 · $597K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Kymera Therapeutics (KYMR): Sold 71,135 at $30.00 on Oct 28, 2022 · $2.1M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Ikena Oncology: Sold 5,959 at $14.00 on Dec 14, 2021 · $83K	Filing · EDGAR
—	—	—	Notice not machine-readable Ikena Oncology: Sold 8,330 at $14.64 on Dec 13, 2021 · $122K	Filing · EDGAR
—	—	—	Notice not machine-readable Ikena Oncology: Sold 11,989 at $15.03 on Dec 10, 2021 · $180K	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 30 at $24.59 on Sep 29, 2021 · $738 (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 16,556 at $24.59 on Sep 29, 2021 · $407K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 24 at $25.24 on Sep 28, 2021 · $606 (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 13,089 at $25.24 on Sep 28, 2021 · $330K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 95 at $25.70 on Sep 27, 2021 · $2K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 51,294 at $25.70 on Sep 27, 2021 · $1.3M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 54 at $25.84 on Sep 24, 2021 · $1K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 28,862 at $25.84 on Sep 24, 2021 · $746K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 140 at $26.13 on Sep 23, 2021 · $4K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 1 at $26.55 on Sep 23, 2021 · $27 (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 75,324 at $26.13 on Sep 23, 2021 · $2M (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 57 at $25.89 on Sep 22, 2021 · $1K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 30,560 at $25.89 on Sep 22, 2021 · $791K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 8 at $26.39 on Jun 24, 2021 · $211 (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 50 at $25.77 on Jun 24, 2021 · $1K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 4,092 at $26.39 on Jun 24, 2021 · $108K (10b5-1 plan)	Filing · EDGAR
—	—	—	Notice not machine-readable Generation Bio (GBIO): Sold 26,858 at $25.77 on Jun 24, 2021 · $692K (10b5-1 plan)	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Kymera Therapeutics KYMR Shareholder · filings 2020 to 2026 · sold $46.1M · $11.9M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 13, 2024	Sale under a 10b5-1 plan	−108,404	$42.19	$4.6M	4,682,761 direct	Filing · EDGAR
Mar 13, 2024	Sale under a 10b5-1 plan	−6,686	$42.84	$286K	4,676,075 direct	Filing · EDGAR
Mar 13, 2024	Sale under a 10b5-1 plan	−22,779	$42.19	$961K	830,216 See footnote	Filing · EDGAR
Mar 13, 2024	Sale under a 10b5-1 plan	−1,386	$42.84	$59K	828,830 See footnote	Filing · EDGAR
Mar 12, 2024	Sale under a 10b5-1 plan	−126,066	$41.94	$5.3M	4,799,746 direct	Filing · EDGAR
Mar 12, 2024	Sale under a 10b5-1 plan	−8,581	$42.52	$365K	4,791,165 direct	Filing · EDGAR
Mar 12, 2024	Sale under a 10b5-1 plan	−26,452	$41.94	$1.1M	854,814 See footnote	Filing · EDGAR
Mar 12, 2024	Sale under a 10b5-1 plan	−1,819	$42.52	$77K	852,995 See footnote	Filing · EDGAR
Mar 11, 2024	Sale under a 10b5-1 plan	−37,180	$42.77	$1.6M	4,930,934 direct	Filing · EDGAR
Mar 11, 2024	Sale under a 10b5-1 plan	−5,122	$43.42	$222K	4,925,812 direct	Filing · EDGAR
Mar 11, 2024	Sale under a 10b5-1 plan	−7,837	$42.77	$335K	882,311 See footnote	Filing · EDGAR
Mar 11, 2024	Sale under a 10b5-1 plan	−1,045	$43.42	$45K	881,266 See footnote	Filing · EDGAR
Jan 12, 2023	Sale under a 10b5-1 plan	−77,128	$30.29	$2.3M	4,968,114 direct	Filing · EDGAR
Jan 12, 2023	Sale under a 10b5-1 plan	−21,592	$30.29	$654K	890,148 See footnote	Filing · EDGAR
Jan 11, 2023	Sale under a 10b5-1 plan	−21,683	$29.96	$650K	5,045,242 direct	Filing · EDGAR
Jan 11, 2023	Sale under a 10b5-1 plan	−6,071	$29.96	$182K	911,740 See footnote	Filing · EDGAR
Dec 15, 2022	Sale under a 10b5-1 plan	−2,561	$30.00	$77K	5,066,925 direct	Filing · EDGAR
Dec 15, 2022	Sale under a 10b5-1 plan	−717	$30.00	$22K	917,811 See footnote	Filing · EDGAR
Dec 14, 2022	Sale under a 10b5-1 plan	−112,819	$30.28	$3.4M	5,252,744 direct	Filing · EDGAR
Dec 14, 2022	Sale under a 10b5-1 plan	−101,189	$31.44	$3.2M	5,151,555 direct	Filing · EDGAR
Dec 14, 2022	Sale under a 10b5-1 plan	−54,737	$32.33	$1.8M	5,096,818 direct	Filing · EDGAR
Dec 14, 2022	Sale under a 10b5-1 plan	−13,997	$33.34	$467K	5,082,821 direct	Filing · EDGAR
Dec 14, 2022	Sale under a 10b5-1 plan	−13,335	$34.02	$454K	5,069,486 direct	Filing · EDGAR
Dec 14, 2022	Sale under a 10b5-1 plan	−31,584	$30.28	$956K	969,833 See footnote	Filing · EDGAR
Dec 14, 2022	Sale under a 10b5-1 plan	−28,329	$31.44	$891K	941,504 See footnote	Filing · EDGAR
Dec 14, 2022	Sale under a 10b5-1 plan	−15,324	$32.33	$495K	926,180 See footnote	Filing · EDGAR
Dec 14, 2022	Sale under a 10b5-1 plan	−3,919	$33.34	$131K	922,261 See footnote	Filing · EDGAR
Dec 14, 2022	Sale under a 10b5-1 plan	−3,733	$34.02	$127K	918,528 See footnote	Filing · EDGAR
Nov 3, 2022	Sale under a 10b5-1 plan	−75,312	$30.00	$2.3M	5,365,563 direct	Filing · EDGAR
Nov 3, 2022	Sale under a 10b5-1 plan	−21,085	$30.00	$633K	1,001,417 See footnote	Filing · EDGAR
Nov 2, 2022	Sale under a 10b5-1 plan	−96,581	$30.02	$2.9M	5,440,875 direct	Filing · EDGAR
Nov 2, 2022	Sale under a 10b5-1 plan	−27,038	$30.02	$812K	1,022,502 See footnote	Filing · EDGAR
Nov 1, 2022	Sale under a 10b5-1 plan	−56,455	$30.57	$1.7M	5,541,183 direct	Filing · EDGAR
Nov 1, 2022	Sale under a 10b5-1 plan	−15,804	$30.57	$483K	1,050,584 See Footnote	Filing · EDGAR
Nov 1, 2022	Sale under a 10b5-1 plan	−3,727	$31.08	$116K	5,537,456 direct	Filing · EDGAR
Nov 1, 2022	Sale under a 10b5-1 plan	−1,044	$31.08	$32K	1,049,540 See Footnote	Filing · EDGAR
Oct 31, 2022	Sale under a 10b5-1 plan	−94,239	$30.23	$2.8M	5,597,638 direct	Filing · EDGAR
Oct 31, 2022	Sale under a 10b5-1 plan	−26,383	$30.23	$798K	1,066,388 See Footnote	Filing · EDGAR
Oct 28, 2022	Sale under a 10b5-1 plan	−71,135	$30.00	$2.1M	5,691,877 direct	Filing · EDGAR
Oct 28, 2022	Sale under a 10b5-1 plan	−19,915	$30.00	$597K	1,092,771 See Footnote	Filing · EDGAR
Aug 25, 2020	Derivative converted	+7,196,584			7,948,982 direct	Filing · EDGAR
Aug 25, 2020	Derivative converted	+1,112,686			1,112,686 See Footnote	Filing · EDGAR
Aug 25, 2020	Derivative converted Series Seed Convertible Preferred Stock	−3,000,000			0 direct	Filing · EDGAR
Aug 25, 2020	Derivative converted Series A Convertible Preferred Stock	−7,000,000			0 direct	Filing · EDGAR
Aug 25, 2020	Derivative converted Series B Convertible Preferred Stock	−1,477,832			0 direct	Filing · EDGAR
Aug 25, 2020	Derivative converted Series C Convertible Preferred Stock	−1,774,624			0 See Footnote	Filing · EDGAR

Generation Bio GBIO 10% owner · filings 2020 to 2026 · sold $6.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 9, 2026	Tendered in a change of control	−711,193	$0.00	$71	0 direct	Filing · EDGAR
Feb 9, 2026	Tendered in a change of control	−116,693	$0.00	$12	0 See footnote	Filing · EDGAR
Feb 9, 2026	Tendered in a change of control	−60	$0.00	$0	0 See footnote	Filing · EDGAR
Sep 29, 2021	Sale under a 10b5-1 plan	−16,556	$24.59	$407K	0 direct	Filing · EDGAR
Sep 29, 2021	Sale under a 10b5-1 plan	−30	$24.59	$738	608 See footnote	Filing · EDGAR
Sep 28, 2021	Sale under a 10b5-1 plan	−13,089	$25.24	$330K	16,556 direct	Filing · EDGAR
Sep 28, 2021	Sale under a 10b5-1 plan	−24	$25.24	$606	638 See footnote	Filing · EDGAR
Sep 27, 2021	Sale under a 10b5-1 plan	−51,294	$25.70	$1.3M	29,645 direct	Filing · EDGAR
Sep 27, 2021	Sale under a 10b5-1 plan	−95	$25.70	$2K	662 See footnote	Filing · EDGAR
Sep 24, 2021	Sale under a 10b5-1 plan	−28,862	$25.84	$746K	80,939 direct	Filing · EDGAR
Sep 24, 2021	Sale under a 10b5-1 plan	−54	$25.84	$1K	757 See footnote	Filing · EDGAR
Sep 23, 2021	Sale under a 10b5-1 plan	−75,324	$26.13	$2M	109,802 direct	Filing · EDGAR
Sep 23, 2021	Sale under a 10b5-1 plan	−1	$26.55	$27	109,801 direct	Filing · EDGAR
Sep 23, 2021	Sale under a 10b5-1 plan	−140	$26.13	$4K	811 See footnote	Filing · EDGAR
Sep 22, 2021	Sale under a 10b5-1 plan	−30,560	$25.89	$791K	185,126 direct	Filing · EDGAR
Sep 22, 2021	Sale under a 10b5-1 plan	−57	$25.89	$1K	951 See footnote	Filing · EDGAR
Sep 17, 2021	Other acquisition or disposition (see the filing)	−1,000,000			7,111,939 direct	Filing · EDGAR
Sep 17, 2021	Other acquisition or disposition (see the filing)	−100,000			1,166,937 See footnote	Filing · EDGAR
Jun 24, 2021	Sale under a 10b5-1 plan	−26,858	$25.77	$692K	4,092 direct	Filing · EDGAR
Jun 24, 2021	Sale under a 10b5-1 plan	−4,092	$26.39	$108K	0 direct	Filing · EDGAR
Jun 24, 2021	Sale under a 10b5-1 plan	−50	$25.77	$1K	616 See footnote	Filing · EDGAR
Jun 24, 2021	Sale under a 10b5-1 plan	−8	$26.39	$211	608 See footnote	Filing · EDGAR
Jun 16, 2021	Other acquisition or disposition (see the filing)	−1,000,000			8,111,939 direct	Filing · EDGAR
Jun 16, 2021	Other acquisition or disposition (see the filing)	−100,000			1,266,937 See footnote	Filing · EDGAR
Dec 15, 2020	Other acquisition or disposition (see the filing)	−1,151,882			11,478,876 See Footnote	Filing · EDGAR
Jun 16, 2020	Derivative converted	+10,040,032			12,630,758 See Footnote	Filing · EDGAR
Jun 16, 2020	Derivative converted Series A Preferred Stock	−15,051,020			0 See Footnote	Filing · EDGAR
Jun 16, 2020	Derivative converted Series C Preferred Stock	−268,269			0 See Footnote	Filing · EDGAR

Disc Medicine GMTX Shareholder · filings 2021 to 2025 · sold $43.9M · $43.6M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Jan 23, 2024	Open-market or private sale	−47,500	$67.65	$3.2M	1,402,186 direct	Filing · EDGAR
Jan 23, 2024	Open-market or private sale	−82,500	$67.65	$5.6M	703,660 See footnote	Filing · EDGAR
Jan 23, 2024	Open-market or private sale	−20,000	$67.65	$1.4M	198,326 See footnote	Filing · EDGAR
Jan 10, 2024	Open-market or private sale	−30,000	$64.00	$1.9M	1,449,686 direct	Filing · EDGAR
Jan 10, 2024	Open-market or private sale	−20,000	$64.00	$1.3M	786,160 See footnote	Filing · EDGAR
Dec 14, 2023	Open-market or private sale	−30,645	$58.27	$1.8M	1,479,866 direct	Filing · EDGAR
Dec 14, 2023	Open-market or private sale	−20,429	$58.27	$1.2M	806,280 See footnote	Filing · EDGAR
Dec 14, 2023	Open-market or private sale	−180	$59.74	$11K	1,479,686 direct	Filing · EDGAR
Dec 14, 2023	Open-market or private sale	−120	$59.74	$7K	806,160 See footnote	Filing · EDGAR
Dec 13, 2023	Open-market or private sale	−5,263	$59.99	$316K	1,510,571 direct	Filing · EDGAR
Dec 13, 2023	Open-market or private sale	−3,508	$59.99	$210K	826,749 See footnote	Filing · EDGAR
Dec 13, 2023	Open-market or private sale	−60	$60.50	$4K	1,510,511 direct	Filing · EDGAR
Dec 13, 2023	Open-market or private sale	−40	$60.50	$2K	826,709 See footnote	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−31,235	$59.87	$1.9M	1,562,550 direct	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−20,823	$59.87	$1.2M	861,401 See footnote	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−632	$60.99	$39K	1,561,918 direct	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−422	$60.99	$26K	860,979 See footnote	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−6,234	$62.42	$389K	1,555,684 direct	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−4,155	$62.42	$259K	856,824 See footnote	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−994	$62.90	$63K	1,554,690 direct	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−665	$62.90	$42K	856,159 See footnote	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−1,031	$63.78	$66K	1,553,659 direct	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−688	$63.78	$44K	855,471 See footnote	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−27,924	$65.10	$1.8M	1,525,735 direct	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−18,615	$65.10	$1.2M	836,856 See footnote	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−9,901	$65.77	$651K	1,515,834 direct	Filing · EDGAR
Dec 12, 2023	Open-market or private sale	−6,599	$65.77	$434K	830,257 See footnote	Filing · EDGAR
Aug 15, 2023	Open-market or private sale	−111,069	$52.40	$5.8M	1,951,234 direct	Filing · EDGAR
Aug 15, 2023	Open-market or private sale	−72,931	$52.40	$3.8M	882,224 See footnote	Filing · EDGAR
Aug 14, 2023	Open-market or private sale	−75,000	$52.00	$3.9M	2,162,303 direct	Filing · EDGAR
Aug 14, 2023	Open-market or private sale	−98,000	$53.00	$5.2M	2,064,303 direct	Filing · EDGAR
Aug 14, 2023	Open-market or private sale	−2,000	$54.80	$110K	2,062,303 direct	Filing · EDGAR
Dec 29, 2022	Other acquisition or disposition (see the filing)	+1,835,799			2,237,303 direct	Filing · EDGAR
Dec 29, 2022	Other acquisition or disposition (see the filing)	+882,224			955,156 See Footnote	Filing · EDGAR

Vigil Neuroscience VIGL 10% owner · filings 2022 to 2025 · bought $7.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 5, 2025	Returned to the company	−4,808,896	$8.00	$38.5M	0 direct	Filing · EDGAR
Aug 5, 2025	Returned to the company	−1,027,978	$8.00	$8.2M	0 By Atlas Venture Opportunity Fund I, L.P.	Filing · EDGAR
Jan 11, 2022	Derivative converted	+2,831,520	$0.00	$283	4,273,896 By Atlas Venture Fund XII, L.P.	Filing · EDGAR
Jan 11, 2022	Derivative converted	+1,027,978	$0.00	$103	1,027,978 By Atlas Venture Opportunity Fund I, L.P.	Filing · EDGAR
Jan 11, 2022	Open-market or private purchase	+535,000	$14.00	$7.5M	4,808,896 By Atlas Venture Fund XII, L.P.	Filing · EDGAR
Jan 11, 2022	Derivative converted Series A Preferred Stock	−7,852,374			0 By Atlas Venture Fund XII, L.P.	Filing · EDGAR
Jan 11, 2022	Derivative converted Series B Preferred Stock	−2,850,789			0 By Atlas Venture Opportunity Fund I, L.P.	Filing · EDGAR

Q32 Bio 10% owner · filings 2024 to 2024

No transactions in the filings read; Form 144 notices are listed above.

Dyne Therapeutics 10% owner · filings 2020 to 2024 · sold $32.4M · bought $10M · $6.4M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Mar 1, 2024	Sale under a 10b5-1 plan	−29,435	$30.05	$885K	1,458,691 direct	Filing · EDGAR
Mar 1, 2024	Sale under a 10b5-1 plan	−17,099	$30.05	$514K	847,388 See footnote	Filing · EDGAR
Feb 28, 2024	Sale under a 10b5-1 plan	−152,244	$24.83	$3.8M	5,700,521 direct	Filing · EDGAR
Feb 28, 2024	Sale under a 10b5-1 plan	−2,430	$25.25	$61K	5,698,091 direct	Filing · EDGAR
Feb 28, 2024	Sale under a 10b5-1 plan	−22,567	$24.83	$560K	1,488,486 See footnote	Filing · EDGAR
Feb 28, 2024	Sale under a 10b5-1 plan	−360	$25.25	$9K	1,488,126 See footnote	Filing · EDGAR
Feb 28, 2024	Sale under a 10b5-1 plan	−13,109	$24.83	$325K	864,697 See footnote	Filing · EDGAR
Feb 28, 2024	Sale under a 10b5-1 plan	−210	$25.25	$5K	864,487 See footnote	Filing · EDGAR
Feb 27, 2024	Sale under a 10b5-1 plan	−272,923	$24.38	$6.7M	5,878,544 direct	Filing · EDGAR
Feb 27, 2024	Sale under a 10b5-1 plan	−25,779	$24.68	$636K	5,852,765 direct	Filing · EDGAR
Feb 27, 2024	Sale under a 10b5-1 plan	−40,455	$24.38	$986K	1,514,874 See footnote	Filing · EDGAR
Feb 27, 2024	Sale under a 10b5-1 plan	−3,821	$24.68	$94K	1,511,053 See footnote	Filing · EDGAR
Feb 27, 2024	Sale under a 10b5-1 plan	−23,505	$24.38	$573K	880,022 See footnote	Filing · EDGAR
Feb 27, 2024	Sale under a 10b5-1 plan	−2,216	$24.68	$55K	877,806 See footnote	Filing · EDGAR
Feb 26, 2024	Sale under a 10b5-1 plan	−136,312	$23.59	$3.2M	6,216,250 direct	Filing · EDGAR
Feb 26, 2024	Sale under a 10b5-1 plan	−64,783	$23.98	$1.6M	6,151,467 direct	Filing · EDGAR
Feb 26, 2024	Sale under a 10b5-1 plan	−20,205	$23.59	$477K	1,564,932 See footnote	Filing · EDGAR
Feb 26, 2024	Sale under a 10b5-1 plan	−9,603	$23.98	$230K	1,555,329 See footnote	Filing · EDGAR
Feb 26, 2024	Sale under a 10b5-1 plan	−11,736	$23.59	$277K	909,107 See footnote	Filing · EDGAR
Feb 26, 2024	Sale under a 10b5-1 plan	−5,580	$23.98	$134K	903,527 See footnote	Filing · EDGAR
Feb 23, 2024	Sale under a 10b5-1 plan	−159,542	$22.70	$3.6M	6,352,562 direct	Filing · EDGAR
Feb 23, 2024	Sale under a 10b5-1 plan	−23,648	$22.70	$537K	1,585,137 See footnote	Filing · EDGAR
Feb 23, 2024	Sale under a 10b5-1 plan	−13,738	$22.70	$312K	920,843 See footnote	Filing · EDGAR
Feb 22, 2024	Sale under a 10b5-1 plan	−119,360	$22.66	$2.7M	6,512,104 direct	Filing · EDGAR
Feb 21, 2024	Sale under a 10b5-1 plan	−149,337	$22.44	$3.4M	6,666,628 direct	Filing · EDGAR
Feb 21, 2024	Sale under a 10b5-1 plan	−35,164	$23.14	$814K	6,631,464 direct	Filing · EDGAR
Dec 12, 2022	Open-market or private purchase	+934,581	$10.70	$10M	934,581 direct	Filing · EDGAR
Sep 21, 2020	Derivative converted	+6,029,726			8,140,130 See footnote	Filing · EDGAR
Sep 21, 2020	Derivative converted	+1,608,785			1,608,785 See footnote	Filing · EDGAR
Sep 21, 2020	Derivative converted Series A Preferred Stock	−20,000,000			0 See footnote	Filing · EDGAR
Sep 21, 2020	Derivative converted Series B Preferred Stock	−5,336,179			0 See footnote	Filing · EDGAR

Xilio Therapeutics 10% owner · filings 2021 to 2024 · sold $4K · bought $3M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 8, 2024	Open-market or private sale	−733	$0.64	$469	2,019,563 direct	Filing · EDGAR
Feb 8, 2024	Open-market or private sale	−267	$0.64	$171	734,546 See footnote	Filing · EDGAR
Jan 12, 2024	Open-market or private sale	−1,540	$0.83	$1K	2,020,296 direct	Filing · EDGAR
Jan 12, 2024	Open-market or private sale	−560	$0.83	$465	734,813 See footnote	Filing · EDGAR
Jan 11, 2024	Open-market or private sale	−1,566	$0.87	$1K	2,021,836 direct	Filing · EDGAR
Jan 11, 2024	Open-market or private sale	−569	$0.87	$495	735,373 See footnote	Filing · EDGAR
Oct 26, 2021	Derivative converted	+1,372,998			1,399,313 See Footnote	Filing · EDGAR
Oct 26, 2021	Derivative converted	+624,089			2,023,402 See Footnote	Filing · EDGAR
Oct 26, 2021	Derivative converted	+548,442			548,442 See Footnote	Filing · EDGAR
Oct 26, 2021	Open-market or private purchase	+187,500	$16.00	$3M	735,942 See Footnote	Filing · EDGAR
Oct 26, 2021	Derivative converted Series A1 Preferred Stock	−13,043,477			0 See Footnote	Filing · EDGAR
Oct 26, 2021	Derivative converted Series B Preferred Stock	−5,928,852			0 See Footnote	Filing · EDGAR
Oct 26, 2021	Derivative converted Series C Preferred Stock	−5,210,204			0 See Footnote	Filing · EDGAR

Third Harmonic Bio 10% owner · filings 2022 to 2022 · bought $5.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 19, 2022	Derivative converted	+6,472,374			10,013,763 direct	Filing · EDGAR
Sep 19, 2022	Open-market or private purchase	+300,000	$17.00	$5.1M	10,313,763 direct	Filing · EDGAR
Sep 19, 2022	Derivative converted	+594,096			594,096 direct	Filing · EDGAR
Sep 19, 2022	Derivative converted Series A-1 Preferred Stock	−3,541,390			0 direct	Filing · EDGAR
Sep 19, 2022	Derivative converted Series A-2 Preferred Stock	−2,282,537			0 direct	Filing · EDGAR
Sep 19, 2022	Derivative converted Series A-3 Preferred Stock	−648,447			0 direct	Filing · EDGAR
Sep 19, 2022	Derivative converted Series B Preferred Stock	−594,096			0 direct	Filing · EDGAR

Day One Biopharmaceuticals 10% owner · filings 2021 to 2022 · bought $19.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 1, 2022	Other acquisition or disposition (see the filing)	−198,280			793,116 direct	Filing · EDGAR
Jun 17, 2022	Open-market or private purchase	+766,667	$15.00	$11.5M	766,667 direct	Filing · EDGAR
Jun 1, 2021	Derivative converted	+7,761,380			7,761,380 See Footnote	Filing · EDGAR
Jun 1, 2021	Derivative converted	+741,396			741,396 See Footnote	Filing · EDGAR
Jun 1, 2021	Open-market or private purchase	+250,000	$16.00	$4M	250,000 See Footnote	Filing · EDGAR
Jun 1, 2021	Open-market or private purchase	+250,000	$16.00	$4M	250,000 See Footnote	Filing · EDGAR
Jun 1, 2021	Derivative converted Series A Preferred Stock	−7,761,380			0 See Footnote	Filing · EDGAR
Jun 1, 2021	Derivative converted Series B Preferred Stock	−741,396			0 See Footnote	Filing · EDGAR
Feb 1, 2021	Open-market or private purchase Series B Preferred Stock	+741,396			741,396 See Footnote	Filing · EDGAR

Ikena Oncology 10% owner · filings 2021 to 2021 · sold $386K · bought $2M

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 14, 2021	Open-market or private sale	−5,959	$14.00	$83K	1,241,935 direct	Filing · EDGAR
Dec 13, 2021	Open-market or private sale	−8,330	$14.64	$122K	1,247,894 direct	Filing · EDGAR
Dec 10, 2021	Open-market or private sale	−11,989	$15.03	$180K	1,256,224 direct	Filing · EDGAR
Mar 30, 2021	Open-market or private purchase	+125,000	$16.00	$2M	874,634 See footnote	Filing · EDGAR
Mar 30, 2021	Derivative converted	+2,901,609			2,901,609 See Footnote	Filing · EDGAR
Mar 30, 2021	Derivative converted	+1,099,118			1,268,213 See Footnote	Filing · EDGAR
Mar 30, 2021	Derivative converted	+749,634			749,634 See Footnote	Filing · EDGAR
Mar 30, 2021	Derivative converted Series A Preferred Stock	−9,499,999			0 See Footnote	Filing · EDGAR
Mar 30, 2021	Derivative converted Series A-1 Preferred Stock	−11,258,117			0 See Footnote	Filing · EDGAR
Mar 30, 2021	Derivative converted Series A-2 Preferred Stock	−7,863,094			0 See Footnote	Filing · EDGAR
Mar 30, 2021	Derivative converted Series B Preferred Stock	−5,362,888			0 See Footnote	Filing · EDGAR

Magenta Therapeutics Other · filings 2020 to 2020

No transactions in the filings read; Form 144 notices are listed above.

Akero Therapeutics 10% owner · filings 2019 to 2020 · bought $4.3M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 7, 2020	Other acquisition or disposition (see the filing)	−50,510			404,079 See footnote	Filing · EDGAR
Dec 17, 2019	Other acquisition or disposition (see the filing)	−520,464			2,949,295 See footnote	Filing · EDGAR
Dec 17, 2019	Other acquisition or disposition (see the filing)	−50,510			454,589 See footnote	Filing · EDGAR
Jun 24, 2019	Derivative converted	+3,469,759			3,469,759 See Footnote	Filing · EDGAR
Jun 24, 2019	Derivative converted	+235,099			235,099 See Footnote	Filing · EDGAR
Jun 24, 2019	Open-market or private purchase	+270,000	$16.00	$4.3M	505,099 See Footnote	Filing · EDGAR
Jun 24, 2019	Derivative converted Series A Preferred Stock	−10,666,667			0 See Footnote	Filing · EDGAR
Jun 24, 2019	Derivative converted Series B Preferred Stock	−722,737			0 See Footnote	Filing · EDGAR

Replimune Group Other · filings 2019 to 2019

No transactions in the filings read; Form 144 notices are listed above.

AVROBIO Other · filings 2019 to 2019

No transactions in the filings read; Form 144 notices are listed above.

All 127 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Oct 21, 2026	Form 144	Could not read	EDGAR
Oct 20, 2026	Form 144	Could not read	EDGAR
Oct 19, 2026	Form 144	Could not read	EDGAR
Sep 4, 2026	Form 144	Could not read	EDGAR
Sep 3, 2026	Form 144	Could not read	EDGAR
Sep 2, 2026	Form 144	Could not read	EDGAR
Aug 14, 2026	Form 144	Could not read	EDGAR
Aug 13, 2026	Form 144	Could not read	EDGAR
Jul 7, 2026	Form 144	Could not read	EDGAR
Jul 6, 2026	Form 144	Could not read	EDGAR
Jun 29, 2026	Form 144	Could not read	EDGAR
Jun 29, 2026	Form 144	Could not read	EDGAR
Jun 26, 2026	Form 144	Could not read	EDGAR
Jun 26, 2026	Form 144	Could not read	EDGAR
Jun 25, 2026	Form 144	Could not read	EDGAR
Jun 25, 2026	Form 144	Could not read	EDGAR
Jun 24, 2026	Form 144	Could not read	EDGAR
Jun 24, 2026	Form 144	Could not read	EDGAR
Jun 23, 2026	Form 144	Could not read	EDGAR
Jun 23, 2026	Form 144	Could not read	EDGAR
Jun 22, 2026	Form 144	Could not read	EDGAR
Jun 18, 2026	Form 144	Could not read	EDGAR
Jun 17, 2026	Form 144	Could not read	EDGAR
May 6, 2026	Form 144	Could not read	EDGAR
May 5, 2026	Form 144	Could not read	EDGAR
May 4, 2026	Form 144	Could not read	EDGAR
Apr 28, 2026	Form 144	Could not read	EDGAR
Apr 27, 2026	Form 144	Could not read	EDGAR
Apr 24, 2026	Form 144	Could not read	EDGAR
Apr 23, 2026	Form 144	Could not read	EDGAR
Apr 22, 2026	Form 144	Could not read	EDGAR
Apr 22, 2026	Form 144	Could not read	EDGAR
Apr 21, 2026	Form 144	Could not read	EDGAR
Apr 20, 2026	Form 144	Could not read	EDGAR
Apr 15, 2026	Form 144	Could not read	EDGAR
Mar 2, 2026	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Feb 9, 2026	Form 4	Generation Bio GBIO	Filing · EDGAR
Dec 17, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Dec 16, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Dec 16, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Dec 15, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Dec 15, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Dec 12, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Dec 12, 2025	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Dec 11, 2025	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Dec 10, 2025	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Oct 17, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Oct 16, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Oct 15, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Oct 8, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Oct 7, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Aug 22, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Aug 14, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Aug 13, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Aug 7, 2025	Form 4	Vigil Neuroscience VIGL	Filing · EDGAR
Aug 5, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Jul 30, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Jul 24, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Jul 23, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Jul 18, 2025	Form 144	Disc Medicine GMTX	Filing · EDGAR
Jul 9, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 13, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Jun 12, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Mar 27, 2024	Form 3	Q32 Bio	Filing · EDGAR
Mar 15, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Mar 14, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Mar 13, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Mar 13, 2024	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Mar 12, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Mar 11, 2024	Form 144	Kymera Therapeutics KYMR	Filing · EDGAR
Mar 5, 2024	Form 4	Dyne Therapeutics	Filing · EDGAR
Mar 5, 2024	Form 144	Disc Medicine GMTX	Filing · EDGAR
Mar 1, 2024	Form 144	Dyne Therapeutics	Filing · EDGAR
Feb 28, 2024	Form 144	Dyne Therapeutics	Filing · EDGAR
Feb 28, 2024	Form 4	Dyne Therapeutics	Filing · EDGAR
Feb 23, 2024	Form 144	Dyne Therapeutics	Filing · EDGAR
Feb 23, 2024	Form 144	Dyne Therapeutics	Filing · EDGAR
Feb 23, 2024	Form 4	Dyne Therapeutics	Filing · EDGAR
Feb 9, 2024	Form 4	Xilio Therapeutics	Filing · EDGAR
Jan 25, 2024	Form 4	Disc Medicine GMTX	Filing · EDGAR
Jan 23, 2024	Form 144	Disc Medicine GMTX	Filing · EDGAR
Jan 16, 2024	Form 4	Xilio Therapeutics	Filing · EDGAR
Jan 12, 2024	Form 4	Disc Medicine GMTX	Filing · EDGAR
Jan 10, 2024	Form 144	Disc Medicine GMTX	Filing · EDGAR
Dec 14, 2023	Form 4	Disc Medicine GMTX	Filing · EDGAR
Dec 12, 2023	Form 144	Disc Medicine GMTX	Filing · EDGAR
Aug 16, 2023	Form 4	Disc Medicine GMTX	Filing · EDGAR
Aug 15, 2023	Form 144	Disc Medicine GMTX	Filing · EDGAR
Jan 13, 2023	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Jan 3, 2023	Form 4	Disc Medicine GMTX	Filing · EDGAR
Dec 16, 2022	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Dec 14, 2022	Form 4	Dyne Therapeutics	Filing · EDGAR
Nov 4, 2022	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Nov 1, 2022	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Sep 19, 2022	Form 4	Third Harmonic Bio	Filing · EDGAR
Sep 14, 2022	Form 3	Third Harmonic Bio	Filing · EDGAR
Jul 6, 2022	Form 4	Day One Biopharmaceuticals	Filing · EDGAR
Jun 22, 2022	Form 4	Day One Biopharmaceuticals	Filing · EDGAR
Jan 11, 2022	Form 4	Vigil Neuroscience VIGL	Filing · EDGAR
Jan 6, 2022	Form 3	Vigil Neuroscience VIGL	Filing · EDGAR
Dec 14, 2021	Form 4	Ikena Oncology	Filing · EDGAR
Oct 26, 2021	Form 4	Xilio Therapeutics	Filing · EDGAR
Oct 21, 2021	Form 3	Xilio Therapeutics	Filing · EDGAR
Sep 29, 2021	Form 4	Generation Bio GBIO	Filing · EDGAR
Sep 24, 2021	Form 4	Generation Bio GBIO	Filing · EDGAR
Sep 21, 2021	Form 4	Generation Bio GBIO	Filing · EDGAR
Jun 28, 2021	Form 4	Generation Bio GBIO	Filing · EDGAR
Jun 21, 2021	Form 4	Generation Bio GBIO	Filing · EDGAR
Jun 2, 2021	Form 4	Day One Biopharmaceuticals	Filing · EDGAR
May 26, 2021	Form 3	Day One Biopharmaceuticals	Filing · EDGAR
Apr 1, 2021	Form 4	Ikena Oncology	Filing · EDGAR
Mar 25, 2021	Form 3	Ikena Oncology	Filing · EDGAR
Feb 11, 2021	Form 3	Disc Medicine GMTX	Filing · EDGAR
Dec 17, 2020	Form 4	Generation Bio GBIO	Filing · EDGAR
Sep 23, 2020	Form 4	Dyne Therapeutics	Filing · EDGAR
Sep 16, 2020	Form 3	Dyne Therapeutics	Filing · EDGAR
Aug 25, 2020	Form 4	Kymera Therapeutics KYMR	Filing · EDGAR
Aug 20, 2020	Form 3	Kymera Therapeutics KYMR	Filing · EDGAR
Jul 13, 2020	Form 3	Magenta Therapeutics	Filing · EDGAR
Jun 18, 2020	Form 4	Generation Bio GBIO	Filing · EDGAR
Jun 11, 2020	Form 3	Generation Bio GBIO	Filing · EDGAR
Feb 10, 2020	Form 4	Akero Therapeutics	Filing · EDGAR
Dec 19, 2019	Form 4	Akero Therapeutics	Filing · EDGAR
Nov 20, 2019	Form 3	Replimune Group	Filing · EDGAR
Jul 29, 2019	Form 3	AVROBIO	Filing · EDGAR
Jun 25, 2019	Form 4	Akero Therapeutics	Filing · EDGAR
Jun 19, 2019	Form 3	Akero Therapeutics	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.